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Adherence to treatment with
non-vitamin K antagonist
anticoagulants: once- vs.
twice-daily regimens
With great interest, we read the article by
Vrijens and Heidbuchel, recently published in
Europace1 focusing on adherence to non-
vitamin K antagonists (NOACs) and translating
studies on modelling HIV treatment to
NOACs. We congratulate the authors for
their excellent work. Indeed, reduced adher-
ence might increase thrombo-embolic and
bleeding complications and seriously impair
the value of NOACs in clinical practice. We
fully agree with the authors that clinical
studies on predictors and consequences of
non-adherence are urgently needed.
However, conclusions for or against a par-
ticular dosing regimen based on theoretical
considerations might be premature due to
several reasons. First, patients with atrial fibril-
lation areoften in need of concomitantmedica-
tion. Limiting the overall number of tablets
taken per day might increase both, adherence
and persistence, to all drugs prescribed. In add-
ition, there is consistent evidence based on
clinical data that adherence in once-daily (QD)
regimen is superior to twice-daily (BID) appli-
cation, in particular with regard to drugs
used to treat cardiovascular diseases. This was
confirmed in a recentmeta-analysis comprising
all trials of drugs used in this setting.2 Secondly,
the pharmacokinetic model mentioned was
created in the context of HIV drugs. However,
overall treatment outcomes for QD and BID
regimen in thesepatientswere similar ina rando-
mized controlled trial, andbenefits for BIDwere
shown in a subgroup of patients only.3 In the
case of rivaroxaban, pharmacokinetics of QD
and BID treatments were extensively tested
and no significant difference in terms of Cmax
andCtroughwas established.
4 Finally, inter-patient
variability of drug levels in NOACs is consider-
able5 and no critically low trough-level is estab-
lished. Since implementation of low molecular
weight heparins we are aware that constant
high drug levels are not absolutely necessary to
achieve an effective anticoagulant treatment.
In conclusion, we fully agree with the
authors that extent of adherence to NOACs
as well as predictors and consequences of non-
adherence are unclear. Clinical studies addres-
sing these issues are urgently needed.
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Medication adherence and
non-vitamin K antagonist oral
anticoagulants: what do we
really know?
In their publication in EP-Europace, Vrijens and
Heidbuchel1 conclude twice-daily (BID) dosing
of non-vitamin K antagonist (VKA) oral anticoa-
gulants ‘may be more forgiving in patients with
suboptimal adherence’ than once-daily (OD)
dosing. The authors submit the above conclusion
is ‘exemplified’ by the PLATO trial, which com-
pared OD clopidogrel to BID ticagrelor in acute
coronary syndrome patients; suggesting the
reduced rate of cardiovascular events with BID
ticagrelor was the result of a ‘greater degree of
continuity of drug action’ in the presence of sub-
optimal adherence.1,2 This theory ignores poten-
tial differences in antiplatelet potency between
agents, in addition to, likely inferior platelet inhib-
ition in some clopidogrel patientswithCYP2C19
genetic polymorphisms.3 These points are more
likely to explain differences in PLATOevent rates
than variances in blood concentrations/activity
subsequent to suboptimal adherence.
Weagreewith the authors that timing adher-
ence (considering both the correct number of
doses taken and their timing) is an important
adherence metric to consider. If one embraces
timing adherence, the authors statement that
the pharmacological equivalent of missing a
single dose of a QD regimen is missing three
consecutive doses of a BID regimen (Figure 2,
panel C) becomes representative of only an
extreme instance of suboptimal adherence.1
The European Heart RhythmAssociation guid-
ance4 on new oral anticoagulants advises a for-
gotten dose can be taken as long as no more
than half the dosing interval has passed. This
means a patient taking an OD regimen need
only remember to take their missed dose
within 12-h of when it was scheduled to catch
up; and consequently, need not go a full 48-h
without a dose as depicted in panel C. It is also
noteworthy that Figure 2 is stated to represent
a single hypothetical drug givenODvs. BID, and
not a comparison of different non-VKA oral
anticoagulants.
Perhaps most importantly, it is unclear what
effect fluctuations in non-VKAoral anticoagula-
tion (measured by drug concentration in the
blood or degrees of factor Xa and/or thrombin
inhibition) will have on efficacy and safety.
Unlike antibiotics, for example, there is a
paucity of data regarding what pharmacoki-
netic/pharmacodynamic parameters are most
important in preventing thrombosis or bleed-
ing. Perhaps the peak-to-trough ratio of the
anticoagulant is most important (a kin to ami-
noglycoside antibiotics), or maybe only a
minimal trough level of anticoagulation activity
above a certain threshold is required to
prevent or treat thrombosis?
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